ASCO Policy Statement on Biosimilar and Interchangeable Products in Oncology. If you have the appropriate software installed, you can download article citation data to the citation manager of your ...

There are 2 different points of the lifecycle of a NICE technology appraisal at which consideration of reference to or inclusion of a biosimilar is appropriate. The procedure for each point is ...

(MENAFN- EIN Presswire) EINPresswire/ -- The Community Oncology Alliance (COA) Board of Directors has issued a new position statement supporting policies that advance biosimilar development and uptake ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family ...

As drug pricing pressure intensifies and benefit structures shift, some health systems are still treating biosimilars as a selective cost lever — deploying them in certain payer segments while ...

"The Association for Accessible Medicines and its Biosimilars Council oppose passage of the PREVAIL Act and the PERA Act. PREVAIL will make it more difficult for generic and biosimilar manufacturers ...

The availability of biosimilar products may improve access to healthcare by increasing the number of therapeutic options available at potentially lower costs. As of April 2019, 18 such biological ...